<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03174613</url>
  </required_header>
  <id_info>
    <org_study_id>LG-SGCL001</org_study_id>
    <nct_id>NCT03174613</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate The Safety, Pharmacokinetics/Pharmacodynamics (PK/PD) and Food Effect Of LC51-0255</brief_title>
  <official_title>A Dose Blocked-randomized, Double-blind, Placebo Controlled, Single and Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamics and Food Effect of LC51-0255</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To evaluate the safety and tolerability of LC51-0255 in healthy male subjects

        2. To evaluate the pharmacokinetic/pharmacodynamics characteristics (PK/PD) of LC51-0255 in
           healthy male subjects

        3. To evaluate bioavailability of LC51-0255
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For safety and tolerability assessement, subjects will be monitored by collection of adverse
      events, physical exams, vital sign, 12-Lead ECG, Continuous ECG monitoring, Holter
      monitoring, blood chemistry and hematology panels, pulmonary function tests, optical
      coherence tomography (OCT) during the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>MTD determination</measure>
    <time_frame>Dose limiting Toxicity will be evaluated at Day 19 in Single dosing study and at Day 39 in Multiple dosing study</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Cmax:168 hours post dose</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>AUCinf:168 hours post dose</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LC51-0255</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablets, PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>tablets, PO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LC51-0255</intervention_name>
    <description>0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg</description>
    <arm_group_label>LC51-0255</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects aged 19~45 years at screening.

          -  Subjects with BMI between 18.0(inclusive) and 27.0 kg/m2 (exclusive)

        Exclusion Criteria:

          -  History or Known presence of clinically relevant hepatic, gastrointestinal, pulmonary,
             psychiatric, endocrine, neurological, cancer, including solid tumors and hematological
             malignancies, cardiovascular, ophthalmological or other major systemic disease

          -  Exclusions Related to Laboratory Results: Platelet count &lt; 100,000/μL, Hgb &lt; 8.5 g/dL,
             Neutrophils &lt; 1.5 /μL, Absolute WBC count &lt; 3500/μL, Absolute lymphocyte count &lt;
             800/μL
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Healthy male subjects</gender_description>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, MD,M.B.A.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital, Clinical Trial Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mina Kim</last_name>
    <phone>82-02-6924-3112</phone>
    <email>minakim@lgchem.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Won Lee, M.D.</last_name>
      <phone>82-2-2072-1666</phone>
      <email>berserk92@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Kyung-Sang Yu, M.D., M.B.A.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2017</study_first_submitted>
  <study_first_submitted_qc>May 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2017</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

